eCQM Title

Discharged on Antithrombotic Therapy

eCQM Identifier (Measure Authoring Tool)

104

eCQM Version Number

10.4.000

NQF Number

Not Applicable

GUID

42bf391f-38a3-4c0f-9ece-dcd47e9609d9

Measurement Period

January 1, 20XX through December 31, 20XX

Measure Steward

The Joint Commission

Measure Developer

The Joint Commission

Endorsed By

None

Description

Ischemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge

Measure specifications are in the Public Domain

LOINC(R) copyright 2004-2020 Regenstrief Institute, Inc. 
This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2020 International Health Terminology Standards Development Organisation. ICD-10 copyright 2020 World Health Organization. All Rights Reserved.

Disclaimer

These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The measures and specifications are provided without warranty.

Measure Scoring

Proportion

Measure Type

Process

Stratification

None

Risk Adjustment

None

Rate Aggregation

None

Rationale

The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity as long as no contraindications exist.

For patients with a stroke due to a cardioembolic source (e.g. atrial fibrillation, mechanical heart valve), warfarin is recommended unless contraindicated. In recent years, novel oral anticoagulant agents (NOACs) have been developed and approved by the U.S. Food and Drug Administration (FDA) for stroke prevention, and may be considered as an alternative to warfarin for select patients. Anticoagulation therapy is not generally recommended for secondary stroke prevention in patients presumed to have a non-cardioembolic stroke.
Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA.

Clinical Recommendation Statement

Clinical trial results suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity as long as no contraindications exist

Improvement Notation

Improvement noted as an increase in rate

Reference

Reference Type: CITATION

Reference Text: 'Adams, H., Adams, R., del Zoppo, G., et al. (2005, April). Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update—A scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke, 36(4): 916-923. '

Reference

Reference Type: CITATION

Reference Text: 'Adams, H. P., Jr., del Zoppo, G., Alberts, M. J., et al. (2007, May). Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke, 38(5), 1655-1711. '

Reference

Reference Type: CITATION

Reference Text: 'Albers, G. W, Amarenco, P., Easton, J. D., et al. (2001). Antithrombotic and thrombolytic therapy for ischemic stroke. Chest, 119, 300-320. '

Reference

Reference Type: CITATION

Reference Text: 'Albers, G. W., Amarenco, P., Easton, J. D., et al. (2004, September). Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126(3), 483S-512S. '

Reference

Reference Type: CITATION

Reference Text: 'Antiplatelet Trialists’ Collaboration. (1994, January 8). Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 308(6921), 81-106. '

Reference

Reference Type: CITATION

Reference Text: 'Antithrombotic Trialists’ Collaboration. (2002, January 12). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ, 324(7329), 71-86. '

Reference

Reference Type: CITATION

Reference Text: 'Bhatt, D. L., Fox, K. A., Hacke, W., et al. (2006, April 20). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine, 354(16), 1706-1717. '

Reference

Reference Type: CITATION

Reference Text: 'Brott, T. G., Clark, W. M., Fagan, S. C., et al. (2000). Stroke: The first hours. Guidelines for acute treatment. Washington, DC: National Stroke Association. '

Reference

Reference Type: CITATION

Reference Text: 'Canadian Cooperative Study Group. (1978, July 13). A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New England Journal of Medicine, 299(2), 53-59.'

Reference

Reference Type: CITATION

Reference Text: 'CAPRIE Steering Committee. (1996, November 16). A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348(9038), 1329-1339.'

Reference

Reference Type: CITATION

Reference Text: 'Centers for Disease Control and Prevention. (2009, May 1). Prevalence and most common causes of disability among adults—United States, 2005. Morbidity and Mortality Weekly Report, 58(16),  421-426. '

Reference

Reference Type: CITATION

Reference Text: 'Chen, Z. M., Sandercock, P., Pan, H. C., et al. (2000, June). Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke, 31(6), 1240-1249. '

Reference

Reference Type: CITATION

Reference Text: 'Coull, B. M., Williams, L. S., Goldstein, L. B., et al. (2002, July). Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Stroke, 33(7), 1934-1942. '

Reference

Reference Type: CITATION

Reference Text: 'Diener, H. C., Bogousslavsky, J., Brass, L. M., et al. (2004, July). Aspirin and lopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet, 364(9431), 331-337. '

Reference

Reference Type: CITATION

Reference Text: 'Dutch Tia Trial Study Group. (1991, October 31). A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine, 325(18), 1261-1266. '

Reference

Reference Type: CITATION

Reference Text: 'Eccles, M., Freemantle, N., & Mason, J. (1998, April 25). North of England Evidence-Based Guideline Development Project: Guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. BMJ, 316(7140), 1303-1309. '

Reference

Reference Type: CITATION

Reference Text: 'ESPRIT Study Group, Halkes, P. H., van Gijn, J., et al. (2006, May 20). Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet, 367(9523), 1665-1673. '

Reference

Reference Type: CITATION

Reference Text: 'ESPS Group. (1987, December 12). The European Stroke Prevention Study (ESPS): Principal end-points. Lancet, 2(8572), 1351-1354. '

Reference

Reference Type: CITATION

Reference Text: 'Farrell, B., Godwin, J., Richards, S., et al. (1991, December). The United Kingdom Transient Ischaemic Attack (Uk-Tia) Aspirin Trial: Final results. Journal of Neurology, Neurosurgery, and Psychiatry, 54(12), 1044-1054. '

Reference

Reference Type: CITATION

Reference Text: 'Gaspoz, J. M., Coxson, P. G., Goldman, P. A., et al. (2002, June 6). Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. New England Journal of Medicine, 346(23), 1800-1806. '

Reference

Reference Type: CITATION

Reference Text: 'Gent, M., Blakely, J. A., Easton, J. D., et al. (1989, June 3). The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1(8649), 1215-1220. '

Reference

Reference Type: CITATION

Reference Text: 'Gorelick, P. B., Richardson, D., Kelly, M., et al. (2003, June 11). Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. JAMA, 289(22), 2947-2957. '

Reference

Reference Type: CITATION

Reference Text: 'Guyatt, G. H., Akl, E. A., Crowther, M., et al. (2012, February). Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2 Suppl.), 7S-47S. '

Reference

Reference Type: CITATION

Reference Text: 'Guyatt, G., Schunemann, H., Cook, D., et al. (2001, January). Grades of recommendation for antithrombotic agents. Chest, 119(1 Suppl.), 3S-7S. '

Reference

Reference Type: CITATION

Reference Text: 'Hass, W. K., Easton, J. D., Adams, H. P., Jr., et al. (1989, August 24). Randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New England Journal of Medicine, 321(8), 501-507. '

Reference

Reference Type: CITATION

Reference Text: 'International Stroke Trial Collaborative Group. (1997, May 31). The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet, 349(9065), 1569-1581. '

Reference

Reference Type: CITATION

Reference Text: 'Jauch, E. C., Saver, J. L., Adams, H. P., Jr., et al. (2013). Guidelines for the early management of patients with acute ischemic stroke: A guideline for health care professionals from the American Heart Association/American Stroke Association. Stroke, 44(3), 870-947. '

Reference

Reference Type: CITATION

Reference Text: 'Johnson, E. S., Lanes, S. F., Wentworth, C. E., III, et al. (1999, June 14). A metaregression analysis of the dose-response effect of aspirin on stroke. Archives of Internal Medicine, 159(11), 1248-1253. '

Reference

Reference Type: CITATION

Reference Text: 'Kennedy, J., Hill, M. D., Ryckborst, K. J., et al. (2007, November). Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): A randomised controlled pilot trial. Lancet Neurology, 6(11): 961-969. '

Reference

Reference Type: CITATION

Reference Text: 'Kernan, W. N., Ovbiagele, B., Black, H. R., et al. (2014, May). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for health care professionals from the American Heart Association/American Stroke Association. Stroke, 45(7), 2160-2223. '

Reference

Reference Type: CITATION

Reference Text: 'Powers, W. J., Rabinstein, A. A., Ackerson, T., et al. (2018, January). 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for health care professionals from the American Heart Association/American Stroke Association. Stroke, 49, e45-e46. '

Reference

Reference Type: CITATION

Reference Text: 'Roger, V. L., Go, A. S., Lloyd-Jones, D. M., et al. (2012, January 3). Heart disease and stroke statistics—2012 update: A report from the American Heart Association. Circulation, 125(1), e2-e220. '

Reference

Reference Type: CITATION

Reference Text: 'Sacco, R. L., Diener, H. C., Yusuf, S., et al. (2008, September 18). Aspirin and Extended-Release Dipyridamole Versus Clopidogrel for Recurrent Stroke. New England Journal of Medicine, 359(12), 1238-1251. '

Reference

Reference Type: CITATION

Reference Text: 'SALT Collaborative Group. (1991, November 30). Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet, 338(8779), 1345-1349. '

Reference

Reference Type: CITATION

Reference Text: 'UK-Tia Study Group. (1988, January 30). United Kingdom Transient Ischaemic Attack (UK-Tia) Aspirin Trial: Interim results. British Medical Journal (Clinical Research Ed.), 296(6618), 316-320. '

Definition

None

Guidance

The "Non-elective Inpatient Encounter" value set intends to capture all non-scheduled hospitalizations. This value set is a subset of the "Inpatient encounter" value set, excluding concepts that specifically refer to elective hospital admissions. Non-elective admissions include emergency, urgent and unplanned admissions.

The "Medication, Discharge" datatype refers to the discharge medication list and is intended to express medications ordered for post-discharge use.

This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period.

This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM.

Transmission Format

TBD

Initial Population

Inpatient hospitalizations for patients age 18 and older, discharged from inpatient care (non-elective admissions) with a principal diagnosis of ischemic or hemorrhagic stroke and a length of stay less than or equal to 120 days that ends during the measurement period

Denominator

Inpatient hospitalizations for patients with a principal diagnosis of Ischemic stroke

Denominator Exclusions

Inpatient hospitalizations for patients admitted for elective carotid intervention. This exclusion is implicitly modeled by only including non-elective hospitalizations.
Inpatient hospitalizations for patients discharged to another hospital
Inpatient hospitalizations for patients who left against medical advice
Inpatient hospitalizations for patients who expired
Inpatient hospitalizations for patients discharged to home for hospice care
Inpatient hospitalizations for patients discharged to a health care facility for hospice care
Inpatient hospitalizations for patients with comfort measures documented

Numerator

Inpatient hospitalizations for patients prescribed or continuing to take antithrombotic therapy at hospital discharge

Numerator Exclusions

Not Applicable

Denominator Exceptions

Inpatient hospitalizations for patients with a documented reason for not prescribing antithrombotic therapy at discharge.
Inpatient hospitalizations for patients who receive Ticagrelor or Prasugrel as an antithrombotic therapy at discharge.

Supplemental Data Elements

For every patient evaluated by this measure also identify payer, race, ethnicity and sex

Population Criteria
Definitions
Functions
Terminology
Data Criteria (QDM Data Elements)
Supplemental Data Elements
Risk Adjustment Variables

Population Criteria

Initial Population

TJC."Encounter with Principal Diagnosis and Age"

- Denominator
  - TJC."Ischemic Stroke Encounter"

Denominator Exclusions

TJC."Ischemic Stroke Encounters with Discharge Disposition"
  union TJC."Encounter with Comfort Measures during Hospitalization"

Numerator

TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter
  with "Antithrombotic Therapy at Discharge" DischargeAntithrombotic
    such that DischargeAntithrombotic.authorDatetime during IschemicStrokeEncounter.relevantPeriod

- Numerator Exclusions
  - None

Denominator Exceptions

"Encounter With No Antithrombotic At Discharge"
  union "Encounter With Pharmacological Contraindications for Antithrombotic Therapy at Discharge"

- Stratification
  - None

Definitions

Antithrombotic Not Given at Discharge

["Medication, Not Discharged": "Antithrombotic Therapy"] NoAntithromboticDischarge
  where NoAntithromboticDischarge.negationRationale in "Medical Reason"
    or NoAntithromboticDischarge.negationRationale in "Patient Refusal"

Antithrombotic Therapy at Discharge

["Medication, Discharge": "Antithrombotic Therapy"]

Denominator
- - TJC."Ischemic Stroke Encounter"

Denominator Exceptions

"Encounter With No Antithrombotic At Discharge"
  union "Encounter With Pharmacological Contraindications for Antithrombotic Therapy at Discharge"

Denominator Exclusions

TJC."Ischemic Stroke Encounters with Discharge Disposition"
  union TJC."Encounter with Comfort Measures during Hospitalization"

Encounter With No Antithrombotic At Discharge

TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter
  with "Antithrombotic Not Given at Discharge" NoDischargeAntithrombotic
    such that NoDischargeAntithrombotic.authorDatetime during IschemicStrokeEncounter.relevantPeriod

Encounter With Pharmacological Contraindications for Antithrombotic Therapy at Discharge

TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter
  with ["Medication, Discharge": "Pharmacological Contraindications For Antithrombotic Therapy"] Pharmacological
    such that Pharmacological.authorDatetime during IschemicStrokeEncounter.relevantPeriod

Initial Population

TJC."Encounter with Principal Diagnosis and Age"

Numerator

TJC."Ischemic Stroke Encounter" IschemicStrokeEncounter
  with "Antithrombotic Therapy at Discharge" DischargeAntithrombotic
    such that DischargeAntithrombotic.authorDatetime during IschemicStrokeEncounter.relevantPeriod

SDE Ethnicity

["Patient Characteristic Ethnicity": "Ethnicity"]

SDE Payer

["Patient Characteristic Payer": "Payer"]

SDE Race
- - ["Patient Characteristic Race": "Race"]

SDE Sex

["Patient Characteristic Sex": "ONC Administrative Sex"]

TJC.All Stroke Encounter

"Non Elective Inpatient Encounter" NonElectiveEncounter
  where exists ( NonElectiveEncounter.diagnoses Diagnosis
      where Diagnosis.rank = 1
        and ( Diagnosis.code in "Hemorrhagic Stroke"
            or Diagnosis.code in "Ischemic Stroke"
        )
  )

TJC.Encounter with Comfort Measures during Hospitalization

"Ischemic Stroke Encounter" IschemicStrokeEncounter
  with "Intervention Comfort Measures" ComfortMeasure
    such that Coalesce(start of Global."NormalizeInterval"(ComfortMeasure.relevantDatetime, ComfortMeasure.relevantPeriod), ComfortMeasure.authorDatetime)during Global."HospitalizationWithObservation" ( IschemicStrokeEncounter )

TJC.Encounter with Principal Diagnosis and Age

"All Stroke Encounter" AllStrokeEncounter
  with ["Patient Characteristic Birthdate": "Birth date"] BirthDate
    such that Global."CalendarAgeInYearsAt" ( BirthDate.birthDatetime, start of AllStrokeEncounter.relevantPeriod ) >= 18

TJC.Intervention Comfort Measures

["Intervention, Order": "Comfort Measures"]
  union ["Intervention, Performed": "Comfort Measures"]

TJC.Ischemic Stroke Encounter

"Encounter with Principal Diagnosis and Age" EncounterWithAge
  where exists ( EncounterWithAge.diagnoses Diagnosis
      where Diagnosis.code in "Ischemic Stroke"
        and Diagnosis.rank = 1
  )

TJC.Ischemic Stroke Encounters with Discharge Disposition

( ( "Ischemic Stroke Encounter" IschemicStrokeEncounter
      where IschemicStrokeEncounter.dischargeDisposition in "Discharge To Acute Care Facility"
        or IschemicStrokeEncounter.dischargeDisposition in "Left Against Medical Advice"
        or IschemicStrokeEncounter.dischargeDisposition in "Patient Expired"
        or IschemicStrokeEncounter.dischargeDisposition in "Discharged to Home for Hospice Care"
        or IschemicStrokeEncounter.dischargeDisposition in "Discharged to Health Care Facility for Hospice Care"
  )
)

TJC.Non Elective Inpatient Encounter

["Encounter, Performed": "Non-Elective Inpatient Encounter"] NonElectiveEncounter
  where Global."LengthInDays" ( NonElectiveEncounter.relevantPeriod ) <= 120
    and NonElectiveEncounter.relevantPeriod ends during day of "Measurement Period"

Functions

Global.CalendarAgeInYearsAt(BirthDateTime DateTime, AsOf DateTime)
- - years between ToDate(BirthDateTime)and ToDate(AsOf)

Global.HospitalizationWithObservation(Encounter "Encounter, Performed")

Encounter Visit
	let ObsVisit: Last(["Encounter, Performed": "Observation Services"] LastObs
			where LastObs.relevantPeriod ends 1 hour or less on or before start of Visit.relevantPeriod
			sort by 
			end of relevantPeriod
	),
	VisitStart: Coalesce(start of ObsVisit.relevantPeriod, start of Visit.relevantPeriod),
	EDVisit: Last(["Encounter, Performed": "Emergency Department Visit"] LastED
			where LastED.relevantPeriod ends 1 hour or less on or before VisitStart
			sort by 
			end of relevantPeriod
	)
	return Interval[Coalesce(start of EDVisit.relevantPeriod, VisitStart), 
	end of Visit.relevantPeriod]

Global.LengthInDays(Value Interval<DateTime>)

difference in days between start of Value and end of Value

Global.NormalizeInterval(pointInTime DateTime, period Interval<DateTime>)

if pointInTime is not null then Interval[pointInTime, pointInTime]
  else if period is not null then period 
  else null as Interval<DateTime>

Global.ToDate(Value DateTime)

DateTime(year from Value, month from Value, day from Value, 0, 0, 0, 0, timezoneoffset from Value)

Terminology

code "Birth date" ("LOINC Code (21112-8)")
valueset "Antithrombotic Therapy" (2.16.840.1.113762.1.4.1110.62)
valueset "Comfort Measures" (1.3.6.1.4.1.33895.1.3.0.45)
valueset "Discharge To Acute Care Facility" (2.16.840.1.113883.3.117.1.7.1.87)
valueset "Discharged to Health Care Facility for Hospice Care" (2.16.840.1.113883.3.117.1.7.1.207)
valueset "Discharged to Home for Hospice Care" (2.16.840.1.113883.3.117.1.7.1.209)
valueset "Emergency Department Visit" (2.16.840.1.113883.3.117.1.7.1.292)
valueset "Ethnicity" (2.16.840.1.114222.4.11.837)
valueset "Hemorrhagic Stroke" (2.16.840.1.113883.3.117.1.7.1.212)
valueset "Ischemic Stroke" (2.16.840.1.113883.3.117.1.7.1.247)
valueset "Left Against Medical Advice" (2.16.840.1.113883.3.117.1.7.1.308)
valueset "Medical Reason" (2.16.840.1.113883.3.117.1.7.1.473)
valueset "Non-Elective Inpatient Encounter" (2.16.840.1.113883.3.117.1.7.1.424)
valueset "Observation Services" (2.16.840.1.113762.1.4.1111.143)
valueset "ONC Administrative Sex" (2.16.840.1.113762.1.4.1)
valueset "Patient Expired" (2.16.840.1.113883.3.117.1.7.1.309)
valueset "Patient Refusal" (2.16.840.1.113883.3.117.1.7.1.93)
valueset "Payer" (2.16.840.1.114222.4.11.3591)
valueset "Pharmacological Contraindications For Antithrombotic Therapy" (2.16.840.1.113762.1.4.1110.52)
valueset "Race" (2.16.840.1.114222.4.11.836)

Data Criteria (QDM Data Elements)

"Encounter, Performed: Emergency Department Visit" using "Emergency Department Visit (2.16.840.1.113883.3.117.1.7.1.292)"
"Encounter, Performed: Non-Elective Inpatient Encounter" using "Non-Elective Inpatient Encounter (2.16.840.1.113883.3.117.1.7.1.424)"
"Encounter, Performed: Observation Services" using "Observation Services (2.16.840.1.113762.1.4.1111.143)"
"Intervention, Order: Comfort Measures" using "Comfort Measures (1.3.6.1.4.1.33895.1.3.0.45)"
"Intervention, Performed: Comfort Measures" using "Comfort Measures (1.3.6.1.4.1.33895.1.3.0.45)"
"Medication, Discharge: Antithrombotic Therapy" using "Antithrombotic Therapy (2.16.840.1.113762.1.4.1110.62)"
"Medication, Discharge: Pharmacological Contraindications For Antithrombotic Therapy" using "Pharmacological Contraindications For Antithrombotic Therapy (2.16.840.1.113762.1.4.1110.52)"
"Medication, Not Discharged: Antithrombotic Therapy" using "Antithrombotic Therapy (2.16.840.1.113762.1.4.1110.62)"
"Patient Characteristic Birthdate: Birth date" using "Birth date (LOINC Code 21112-8)"
"Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity (2.16.840.1.114222.4.11.837)"
"Patient Characteristic Payer: Payer" using "Payer (2.16.840.1.114222.4.11.3591)"
"Patient Characteristic Race: Race" using "Race (2.16.840.1.114222.4.11.836)"
"Patient Characteristic Sex: ONC Administrative Sex" using "ONC Administrative Sex (2.16.840.1.113762.1.4.1)"

Supplemental Data Elements

SDE Ethnicity

["Patient Characteristic Ethnicity": "Ethnicity"]

SDE Payer

["Patient Characteristic Payer": "Payer"]

SDE Race
- - ["Patient Characteristic Race": "Race"]

SDE Sex

["Patient Characteristic Sex": "ONC Administrative Sex"]

Risk Adjustment Variables

None

Measure Set

eMeasure Stroke (eSTK)